Xenetic Biosciences, Inc. to Present at BIO Investor Forum
Xenetic Biosciences, Inc. Provides Business Outlook
Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform
Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Xenetic Biosciences, Inc. Reports First Quarter 2019 Financial Results and Provides Corporate Update
Xenetic Biosciences, Inc. Strengthens Scientific Advisory Board with Appointment of Guenther Koehne, M.D., Ph.D.
Xenetic Biosciences, Inc. Reports 2018 Year End Results and Provides Corporate Update
